Trials / Recruiting
RecruitingNCT04109755
Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer
A Phase II Study to Evaluate Safety and Efficacy of Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- University Hospital, Geneva · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This project investigates the clinical and biological impact of combining immunotherapy (pembrolizumab) with short course radiotherapy (5Gy, five times) in the neo-adjuvant treatment of localised microsatellite stable (MSS) rectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | 5x5 Gy radiotherapy in 1 week, 4 cycles of Pembrolizumab (200 mg every three week), surgery |
Timeline
- Start date
- 2020-06-02
- Primary completion
- 2022-06-01
- Completion
- 2028-03-01
- First posted
- 2019-09-30
- Last updated
- 2021-09-30
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT04109755. Inclusion in this directory is not an endorsement.